Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent.

ABSTRACT: With advances in biomarker-based detection of Alzheimer's disease (AD) and new treatment options with disease-modifying treatments (DMTs), we are heading toward a new conceptualization of diagnostics and therapy in the early stages of AD. Yet consensus guidelines on best clinical practices in predictive AD diagnostics are still developing. Currently, there is a knowledge gap regarding counseling and disclosure practices in early symptomatic disease stages, its implications for dementia risk estimation, and DMTs with associated risks and benefits. The crucial feature is the capacity of patients with (mild) cognitive impairment, eligible for DMTs, to consent. This perspective aims to (1) discuss the current challenges in assessing capacity to consent and (2) highlight the importance of a sup

SUBMITTER: Karneboge J 

PROVIDER: S-EPMC11772727 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature